A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Irene M GhobrialChia-Jen LiuRobert A ReddRaymond P PerezRachid BazOksana ZavidijRomanos Sklavenitis-PistofidisPaul G RichardsonKenneth C AndersonJacob LaubachPatrick HenrickAlexandra SavellKaitlen ReyesKalvis HornburgStacey ChumaPeter SabbatiniMichael D RobbinsPamela S BeckerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study showed that blockade of the CXCR4-CXCL12 axis by ulocuplumab is safe with acceptable AEs and leads to a high response rate in combination with lenalidomide and dexamethasone in patients with relapsed/refractory myeloma, making CXCR4 inhibitors a promising class of antimyeloma drugs that should be further explored in clinical trials.